# FNI Venture Capital

> FNI Venture Capital is a VC fund in Ipswich backing Medical, Health Care and Pharmaceutical. See 3 investments, round sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Ipswich, United Kingdom
- Total investments: 3
- Last investment: Jun 2007
- Lead investor: 0%
- Last updated: Aug 2026

FNI Venture Capital is an investment arm of Renate Nixdorf Verwaltungsgesellschaft mbH.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 67% |
| Health Care | 2 | 67% |
| Pharmaceutical | 2 | 67% |
| Life Science | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 33% |
| Series B | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Germany | 1 | 33% |
| United Kingdom | 1 | 33% |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Antenova | Antenova, Ltd. engages in the design, development, and supply of standard and custom antennas, and radio frequency antenna modules. Its products are used in mobile handsets, adapters, portable devices, laptop computers, and wireless devices. Antenova, Ltd. was incorporated in 1999 and is headquartered in Stow-cum-Quy, the United Kingdom. It hasdesign, and sales and support centers in Taipei, Taiwan; Chicago, Illinois; and Shanghai, China, as well as manufacturing operations in Taiwan and China. | $10M |  | Jun 06, 2007 |  |
| Spinal Cord Therapeutics GmbH | Spinal Cord Therapeutics GmbH develops treatments for spinal cord injury. Spinal Cord Therapeutics focuses on the treatment of traumatic injury to the central nervous system. | $14M | Series A | Sep 19, 2005 |  |
| De Novo Pharmaceuticals | De Novo Pharmaceuticals is an emerging computational drug design company. De Novo Pharmaceuticals uses its proprietary computational software for drug design to create novel, patentable lead molecules as candidates for drug development. De Novo's proprietary algorithms can convert information from structural genomics and medicinal chemistryrapidly into new chemical designs, maximising value within a pharmaceutical partner's research portfolio. De Novo's drug discovery partners include British Biotechnology, Aventis Pharmaceuticals and NV Organon. | $22M | Series B | Jul 26, 2001 |  |

3 of 3 investments shown.

## Co-investors
- The Cambridge Gateway Fund — VC Fund, 2 deals together
- [Artemis](https://shizune.co/investors/profile/artemis) — VC Fund, 1 deal together
- [Avlar BioVentures](https://shizune.co/investors/profile/avlar-bioventures) — VC Fund, 1 deal together
- [BioMedPartners](https://shizune.co/investors/profile/biomedpartners) — VC Fund, 1 deal together
- CLS Holdings — VC Fund, 1 deal together
- [Global Life Science Ventures](https://shizune.co/investors/profile/global-life-science-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does FNI Venture Capital invest in?

FNI Venture Capital invests primarily in Medical, Health Care and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did FNI Venture Capital last invest?

The most recent investment recorded for FNI Venture Capital closed in Jun 2007. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co